Massachusetts Medical Society, New England Journal of Medicine, 11(350), p. 1081-1092
DOI: 10.1056/nejmoa040331
Taylor & Francis, Women's Oncology Review, 2(4), p. 127-128
DOI: 10.1080/14733400410001728483
Taylor & Francis, Women's Oncology Review, 2(4), p. 127-128
DOI: 10.3109/14733400410001728483
Full text: Download
BACKGROUND: Tamoxifen, taken for five years, is the standard adjuvant treatment for postmenopausal women with primary, estrogen-receptor-positive breast cancer. Despite this treatment, however, some patients have a relapse. METHODS: We conducted a double-blind, randomized trial to test whether, after two to three years of tamoxifen therapy, switching to exemestane was more effective than continuing tamoxifen therapy for the remainder of the five years of treatment. The primary end point was disease-free survival. RESULTS: Of the 4742 patients enrolled, 2362 were randomly assigned to switch to exemestane, and 2380 to continue to receive tamoxifen. After a median follow-up of 30.6 months, 449 first events (local or metastatic recurrence, contralateral breast cancer, or death) were reported--183 in the exemestane group and 266 in the tamoxifen group. The unadjusted hazard ratio in the exemestane group as compared with the tamoxifen group was 0.68 (95 percent confidence interval, 0.56 to 0.82; P